Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Bristol-Myers Squibb
Canadian Cancer Trials Group
SWOG Cancer Research Network
Regeneron Pharmaceuticals
Rigshospitalet, Denmark
RenJi Hospital
Cancer Research UK
Alpha Biopharma (Jiangsu) Co., Ltd.
SWOG Cancer Research Network